Cancer News and Research

Latest Cancer News and Research

Geriatric Surgery Verification program enhances postoperative outcomes for older cancer patients

Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification (GSV) program leads to better postoperative outcomes and preserves independence in older cancer patients undergoing major abdominal procedures, according to a new study published in the Journal of the American College of Surgeons

10 Dec 2024

Public awareness and HPV vaccination rates remain low among American adults

The human papillomavirus (HPV), a common sexually transmitted infection, accounts for 70% of all throat cancers, according to the National Cancer Institute.

10 Dec 2024

Toxic chemical exposure in early life linked to behavioral problems in rats

Early life exposure to a class of endocrine-disrupting chemicals (EDCs) called polychlorinated biphenyls (PCBs) may lead to behavioral problems in rats, according to a new animal study published in the Journal of the Endocrine Society.

10 Dec 2024

Study unveils how Toxoplasma gondii parasites escape drug treatment

A study by Indiana University School of Medicine researchers sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.

10 Dec 2024

Two distinct types of fatty liver disease identified

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease - a liver-specific type and a systemic type that affects other organs and tissues.

10 Dec 2024

Sweet news: Dark chocolate reduces type 2 diabetes risk

Findings show dark chocolate may lower type 2 diabetes risk, while milk chocolate contributes to weight gain. Implications for dietary choices discussed.

10 Dec 2024

Microplastics detected in human blood linked to altered coagulation markers

Findings indicate microplastics in blood are linked to inflammation and coagulation markers, underscoring the need for reduced exposure and further research.

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

Smoking linked to increased genetic mutations in myelodysplastic syndromes

Smokers with myelodysplastic syndromes (MDS) or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024

New advances offer hope for patients with systemic mastocytosis

Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately diagnose and treat.

9 Dec 2024

Study provides the first evidence of genetic predisposition to breast cancer metastasis

Ninety percent of cancer deaths are due to the spread of cancer, not complications from the original tumor.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

47th annual San Antonio Breast Cancer Symposium kicks off in December

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 10-13.

9 Dec 2024

Lab-grown tumor organoids predict patient response to CAR T cell therapy

For the first time, researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

9 Dec 2024

Two new subtypes of MASH revealed with different risks and outcomes

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.

9 Dec 2024

Soft tissue sarcoma rates vary between active-duty military servicemen and general population

A recent analysis reveals that the incidence rates of soft tissue sarcomas - cancers in muscle, fat, blood vessels, nerves, and tendons - are lower in young U.S. active-duty military servicemen compared with those in the general population, but higher in middle-aged servicemen, perhaps due to greater cumulative exposure to toxins.

9 Dec 2024

New immunotherapeutic platform improves mRNA therapy efficacy against cancer

Therapeutic mRNAs offer great potential as a versatile and precise tool against cancer and other diseases.

9 Dec 2024

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

9 Dec 2024